ダウンロード数: 390
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
66_12_427.pdf | 767.71 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | 安川, 瞳 | ja |
dc.contributor.author | 池端, 良紀 | ja |
dc.contributor.author | 坪井, 康真 | ja |
dc.contributor.author | 西山, 直隆 | ja |
dc.contributor.author | 渡部, 明彦 | ja |
dc.contributor.author | 藤内, 靖喜 | ja |
dc.contributor.author | 北村, 寛 | ja |
dc.contributor.alternative | Yasukawa, Hitomi | en |
dc.contributor.alternative | Ikehata, Yoshinori | en |
dc.contributor.alternative | Tsuboi, Yasumasa | en |
dc.contributor.alternative | Nishiyama, Naotaka | en |
dc.contributor.alternative | Watanabe, Akihiko | en |
dc.contributor.alternative | Fujiuchi, Yasuyoshi | en |
dc.contributor.alternative | Kitamura, Hiroshi | en |
dc.contributor.transcription | ヤスカワ, ヒトミ | ja-Kana |
dc.contributor.transcription | イケハタ, ヨシノリ | ja-Kana |
dc.contributor.transcription | ツボイ, ヤスマサ | ja-Kana |
dc.contributor.transcription | ニシヤマ, ナオタカ | ja-Kana |
dc.contributor.transcription | ワタナベ, アキヒコ | ja-Kana |
dc.contributor.transcription | フジウチ, ヤスヨシ | ja-Kana |
dc.contributor.transcription | キタムラ, ヒロシ | ja-Kana |
dc.date.accessioned | 2021-01-13T23:54:41Z | - |
dc.date.available | 2021-01-13T23:54:41Z | - |
dc.date.issued | 2020-12-31 | - |
dc.identifier.issn | 0018-1994 | - |
dc.identifier.uri | http://hdl.handle.net/2433/260985 | - |
dc.description.abstract | Abiraterone acetate plus prednisone/prednisolone (AAP) and androgen deprivation therapy (ADT) was approved for the treatment of high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in Japan in 2018. We investigated 22 patients with mHSPC showing ≥2 of 3 high-risk factors (Gleason score ≥8, ≥3 bone lesions or measurable visceral metastases) who received AAP plus ADT at our hospital between March 2018 and October 2019. We compared outcomes between the propensity-score matched AAP plus ADT group and the combined androgen blockade (CAB) group (19 matched pairs, 38 patients) to evaluate the efficacy and safety of AAP plus ADT. Prostate-specific antigen progression-free survival (PSA-PFS) was significantly longer in the AAP group than in the CAB group (not reached vs 15.1 months, p=0.014). Time to achievement of serum PSA ≤0.2 ng/ml and ≤0.1 ng/ml was shorter in the AAP group than in the CAB group (6.4 months vs not reached, p=0.001 and 11.0 months vs not reached, p=0.004, respectively). Although no significant intergroup difference was observed in the overall survival rates and PSA-PFS2 (PSAPFS on subsequent anticancer therapy) owing to the shorter follow-up in the AAP group, our data suggest that the clinical efficacy of AAP is betterthan that of CAB in patients with mHSPC. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | jpn | - |
dc.publisher | 泌尿器科紀要刊行会 | ja |
dc.rights | 許諾条件により本文は2022/01/01に公開 | ja |
dc.subject | Abiraterone acetate | en |
dc.subject | Metastatic hormone-sensitive prostate cancer | en |
dc.subject.ndc | 494.9 | - |
dc.title | 転移性ホルモン感受性前立腺癌に対する アンドロゲン除去療法とアビラテロン酢酸エステル + 低用量プレドニゾロン療法の当院での初期治療経験 --複合アンドロゲン遮断療法との有効性と安全性の比較検討-- | ja |
dc.title.alternative | Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer | en |
dc.type | departmental bulletin paper | - |
dc.type.niitype | Departmental Bulletin Paper | - |
dc.identifier.ncid | AN00208315 | - |
dc.identifier.jtitle | 泌尿器科紀要 | ja |
dc.identifier.volume | 66 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 427 | - |
dc.identifier.epage | 432 | - |
dc.textversion | publisher | - |
dc.sortkey | 02 | - |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address | 富山大学学術研究部医学系腎泌尿器科学 | ja |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.address.alternative | The Department of Urology, University of Toyama | en |
dc.identifier.pmid | 33435652 | - |
dc.identifier.selfDOI | 10.14989/ActaUrolJap_66_12_427 | - |
dcterms.accessRights | open access | - |
datacite.date.available | 2022-01-01 | - |
dc.identifier.pissn | 0018-1994 | - |
dc.identifier.jtitle-alternative | Acta urologica Japonica | la |
dc.identifier.jtitle-alternative | Hinyokika Kiyo | en |
出現コレクション: | Vol.66 No.12 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。